Table 2 Treatment effect of high and low-dose PXT3003 vs placebo in exploratory efficacy endpoints (mFAS)
Test | High-dose PXT3003 | Low-dose PXT3003 | |
|---|---|---|---|
ONLS | Arm score (↓) | − 0.19 (− 0.43, 0.04) | 0.01 (− 0.19, 0.22) |
Leg score (↓) | − 0.18 (− 0.36, 0.01) | − 0.13 (− 0.29, 0.02) | |
QMT | Grip strength (↑) (kg) | − 1.49 (− 3.92, 0.93) | 0.37 (− 1.64, 2.37) |
Dorsiflexion strength (↑) (Newton) | 7.48 (− 3.60, 18.57) | 4.09 (− 5.01, 13.20) | |
Electrophysiology | CMAP (↑) (mV) | − 0.33 (− 1.05, 0.40) | 0.14 (− 0.46, 0.74) |
Motor nerve conduction velocity (↑) (m/s) | 0.08 (− 1.52, 1.67) | − 0.09 (− 1.42, 1.25) | |
Distal motor latency (↓) (ms) | − 0.20 (− 1.58, 1.18) | 0.08 (− 1.07, 1.24) | |
Radial SNAP (↑) (µV) | − 0.11 (− 1.20, 0.99) | − 0.04 (− 0.96, 0.88) | |
Quality of life | Mobility (↓) | − 0.07 (− 0.35, 0.20) | − 0.11 (− 0.34, 0.12) |
Self-care (↓) | − 0.12 (− 0.31, 0.06) | − 0.18 (− 0.34, − 0.03) | |
Usual activities (↓) | − 0.02 (− 0.27, 0.23) | − 0.11 (− 0.32, 0.10) | |
Pain/discomfort (↓) | 0.00 (− 0.25, 0.26) | − 0.12 (− 0.33, 0.09) | |
Anxiety/depression (↓) | − 0.04 (− 0.29, 0.22) | − 0.06 (− 0.28, 0.15) | |
Visual analog scale (↑) (mm) | 2.57 (− 2.36, 7.50) | 4.67 (0.59, 8.75) |